Become a Patron!

Announces First Participants Dosed In Phase 1/2a HEADLINE Trial

Status
Not open for further replies.

VUBot

Staff member
Diamond Contributor
ECF Refugee
Vape Media
ef3f024e946dd923_sq.webp


Absci Corporation (NASDAQ:ABSI) is among the 12 Best Genomics Stocks to Invest In. Absci Corporation (NASDAQ:ABSI) announced on December 4, 2025, that the first healthy volunteers had been dosed in the Phase 1/2a HEADLINE clinical trial investigating ABS-201, an experimental anti-prolactin…

Continue reading...
 
Status
Not open for further replies.

VU Sponsors

Top